[go: up one dir, main page]

PL2729143T3 - Stosowanie biotyny do leczenia stwardnienia rozsianego - Google Patents

Stosowanie biotyny do leczenia stwardnienia rozsianego

Info

Publication number
PL2729143T3
PL2729143T3 PL13719836T PL13719836T PL2729143T3 PL 2729143 T3 PL2729143 T3 PL 2729143T3 PL 13719836 T PL13719836 T PL 13719836T PL 13719836 T PL13719836 T PL 13719836T PL 2729143 T3 PL2729143 T3 PL 2729143T3
Authority
PL
Poland
Prior art keywords
biotin
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
PL13719836T
Other languages
English (en)
Polish (pl)
Inventor
Frédéric Sedel
Original Assignee
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique filed Critical Hopitaux Paris Assist Publique
Publication of PL2729143T3 publication Critical patent/PL2729143T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13719836T 2012-07-26 2013-04-29 Stosowanie biotyny do leczenia stwardnienia rozsianego PL2729143T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1257254A FR2993780B1 (fr) 2012-07-26 2012-07-26 Methode de traitement de la sclerose en plaque
US13/644,615 US8835487B2 (en) 2012-07-26 2012-10-04 Method of treating multiple sclerosis
PCT/EP2013/058936 WO2014016003A1 (fr) 2012-07-26 2013-04-29 Utilisation de biotine pour le traitement de la sclérose en plaques
EP13719836.2A EP2729143B1 (fr) 2012-07-26 2013-04-29 UTILISATION DE la BIOTINE POUR LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES

Publications (1)

Publication Number Publication Date
PL2729143T3 true PL2729143T3 (pl) 2015-05-29

Family

ID=47294963

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13719836T PL2729143T3 (pl) 2012-07-26 2013-04-29 Stosowanie biotyny do leczenia stwardnienia rozsianego

Country Status (25)

Country Link
US (5) US8835487B2 (fr)
EP (2) EP2857019B1 (fr)
JP (1) JP6208235B2 (fr)
KR (1) KR101967502B1 (fr)
CN (2) CN109908140A (fr)
AU (1) AU2013295370B2 (fr)
BR (1) BR112015001562A2 (fr)
CA (1) CA2879434C (fr)
CY (1) CY1116304T1 (fr)
DK (2) DK2857019T3 (fr)
EA (1) EA030478B1 (fr)
ES (3) ES2811074T3 (fr)
FR (1) FR2993780B1 (fr)
HK (1) HK1207583A1 (fr)
HR (1) HRP20150260T1 (fr)
HU (1) HUE024558T2 (fr)
IL (1) IL236790A (fr)
LT (1) LT2857019T (fr)
ME (1) ME02060B (fr)
PL (1) PL2729143T3 (fr)
PT (2) PT2857019T (fr)
RS (1) RS53893B1 (fr)
SI (2) SI2857019T1 (fr)
SM (1) SMT201500057B (fr)
WO (1) WO2014016003A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
CA2910717C (fr) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotine pour son utilisation dans le traitement d'une adrenoleucodystrophie liee a l'x
EP3257881B1 (fr) * 2015-02-13 2020-09-02 Unimatec Co., Ltd. Copolymère fluoré, et agent de modification de surface le contenant en tant que principe actif
EP3072513A1 (fr) * 2015-03-26 2016-09-28 Medday Biotin pour le traitement de la sclérose latérale amyotrophique
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
RU2638803C2 (ru) * 2016-06-09 2017-12-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки биотина с замедленным высвобождением и способ их получения
RU2611415C1 (ru) * 2015-11-17 2017-02-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты)
WO2017086835A1 (fr) * 2015-11-17 2017-05-26 Общество С Ограниченной Ответственностью "Валента-Интеллект" Composition pharmaceutique possédant un effet thérapeutique vis-à-vis des maladies démyélinisantes (et variantes)
EP3275439A1 (fr) 2016-07-29 2018-01-31 Medday Pharmaceuticals Procédé de traitement de l'encéphalopathie hépatique
CN109890384A (zh) 2016-09-01 2019-06-14 Jds治疗有限公司 生物素镁组合物和使用方法
RU2639488C1 (ru) * 2017-04-06 2017-12-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" Фармацевтическая композиция, содержащая биотин, и способ ее получения
US20200155510A1 (en) * 2018-11-13 2020-05-21 Jds Therapeutics, Llc Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions
CN112076310A (zh) * 2019-06-14 2020-12-15 苏州融析生物科技有限公司 一种治疗多发性硬化的药物组合物及其制备
AU2020407071A1 (en) 2019-12-16 2022-07-07 Nutrition 21, Llc Methods of production of arginine-silicate complexes
CA3157712C (fr) 2020-01-01 2024-01-23 Jotiram PALKAR Compositions nutritionnelles synergiques pour ameliorer l'efficacite de l'atp cellulaire

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3609165A (en) 1968-07-19 1971-09-28 Research Corp 1,3-diazabicyclo {8 3.1.0{9 {0 hex-3-enes
JPH0995448A (ja) 1995-09-29 1997-04-08 Calpis Food Ind Co Ltd:The 血中ビオチン濃度の増加方法およびビオチン含有飲食品
EP0891719A1 (fr) * 1997-07-14 1999-01-20 N.V. Nutricia Composition dietique contenant de la methionine
US5789401A (en) 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US6664039B1 (en) 1998-10-14 2003-12-16 California Institute Of Technology Methods and compositions for modulating neurodegeneration
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE19903241A1 (de) 1999-01-28 2000-08-03 Merck Patent Gmbh Galenische Formulierung
AU2003266287A1 (en) 2002-08-23 2004-03-11 Dsm Ip Assets B.V. Novel nutraceutical compositions comprising biotin
DE60333207D1 (de) 2002-09-30 2010-08-12 Daiichi Sankyo Co Ltd Pantethin enthaltendes teilchenförmiges produkt
DE10341240A1 (de) * 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU2003300167B2 (en) * 2003-12-31 2010-09-16 K-Pax Vitamins, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
IL162288A0 (en) * 2004-06-01 2005-11-20 Future Products Man S A Compositions and methods for treating neurodegenerative disorders
BG66011B1 (bg) * 2005-05-25 2010-10-29 Райна Щонова Състав от растителен произход
WO2011077239A2 (fr) 2009-12-23 2011-06-30 Lupin Limited Compositions pharmaceutiques d'ilopéridone à libération lente
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque

Also Published As

Publication number Publication date
US20190117626A1 (en) 2019-04-25
KR20150042799A (ko) 2015-04-21
WO2014016003A1 (fr) 2014-01-30
JP6208235B2 (ja) 2017-10-04
EP2729143B1 (fr) 2014-12-31
DK2857019T3 (da) 2020-08-17
CA2879434A1 (fr) 2014-01-30
ES2532364T3 (es) 2015-03-26
HUE024558T2 (hu) 2016-02-29
SMT201500057B (it) 2015-05-05
RS53893B1 (sr) 2015-08-31
JP2015522630A (ja) 2015-08-06
EP2857019A1 (fr) 2015-04-08
EA201590270A1 (ru) 2015-11-30
EP2729143A1 (fr) 2014-05-14
ME02060B (me) 2015-05-20
PT2857019T (pt) 2020-07-24
FR2993780A1 (fr) 2014-01-31
CA2879434C (fr) 2019-04-23
FR2993780B1 (fr) 2015-02-13
US9351961B2 (en) 2016-05-31
US20190117625A1 (en) 2019-04-25
AU2013295370A1 (en) 2015-02-19
KR101967502B1 (ko) 2019-04-09
EP2857019B1 (fr) 2020-05-27
LT2857019T (lt) 2020-09-10
BR112015001562A2 (pt) 2017-07-04
CN109908140A (zh) 2019-06-21
CY1116304T1 (el) 2017-02-08
EA030478B1 (ru) 2018-08-31
IL236790A (en) 2017-09-28
US20140030331A1 (en) 2014-01-30
US20160324830A1 (en) 2016-11-10
US20140348920A1 (en) 2014-11-27
ES2626079T3 (es) 2017-07-21
CN104602689A (zh) 2015-05-06
SI2857019T1 (sl) 2020-10-30
AU2013295370B2 (en) 2017-03-02
ES2811074T3 (es) 2021-03-10
US8835487B2 (en) 2014-09-16
SI2729143T1 (sl) 2015-05-29
PT2729143E (pt) 2015-03-16
HK1207583A1 (en) 2016-02-05
US10201528B2 (en) 2019-02-12
DK2729143T3 (en) 2015-03-23
HRP20150260T1 (hr) 2015-05-08

Similar Documents

Publication Publication Date Title
PT2729143E (pt) Utilização de biotina para o tratamento de esclerose múltipla
SI2879672T1 (sl) Kombinirana terapija za zdravljenje multiple skleroze
GB2502557B8 (en) Analogue-to-digital converter
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
PL2928477T3 (pl) Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy
ZA201406082B (en) Use of ccr3-inhibitors
EP2758780A4 (fr) Méthode de traitement de la sclérose en plaques
IL240014A0 (en) Treatment of multiple sclerosis using laquinimod
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
EP2812190A4 (fr) Composition de traitement de surface
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
SI2812351T1 (sl) Farmacevtski sestavek za zdravljenje multiple skleroze
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
IL228464A (en) Quinolone analogues for use in the preparation of MS drugs
ZA201501109B (en) Hard surface treatment composition
GB201210184D0 (en) Formulations of metronidazole for the treatment of pouchitis
AP2015008270A0 (en) Preparation for the treatment of tuberculosis
GB201212604D0 (en) New treatment
GB201112716D0 (en) Pandora 2
PH32012000666S1 (en) Oval basin
PL399422A1 (pl) Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu
PL399423A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
PL398695A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
GB201221362D0 (en) Inhibiting the decomposition of acidulants